A potential preclinical migraine model: CGRP-sensitized mice

Molecular and Cellular Pharmacology

Volumn 1, Issue 5, 2009, Pages 264-270

  Russo, Andrew F ^a   Kuburas, Adisa ^a   Kaiser, Eric A ^a   Raddant, Ann C ^a   Recober, Ana ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Calcitonin gene related peptide; Migraine; Photophobia; Receptor activity modifying protein 1; Transgenic mouse

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; NESTIN; OLCEGEPANT; RECEPTOR ACTIVITY MODIFYING PROTEIN 1;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; MIGRAINE; MOUSE; NONHUMAN; NOTE; PHOTOPHOBIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; TRANSGENIC MOUSE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77953461921     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.09.32     Document Type: Note

References (58)

1. Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983;304:129-35.
2. Russo AF, Dickerson IM. CGRP: A multifunctional neuropeptide. In: Lajtha A, ed. Handboook of Neurochemistry and Molecular Neurobiology. 3rd ed. New York, NY: Springer; 2006:391-426.
3. Recober A, Russo AF. Calcitonin gene-related peptide: an update on the biology. Curr Opin Neurol 2009;22:241-6.
4. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004;500:315-30.
5. Durham PL. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 2008;48:1269-75.
6. Edvinsson L. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets 2007;11:1179-88.
7. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007;28:580-7.
8. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurology 1990;28:183-7.
9. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
10. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 2005;58:561-8.
11. Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain 2009;10:137-43.
12. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005;25:179-83.
13. Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 2006;46:24-33.
14. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49:1258-66.
15. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61.
16. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005;77:202-13.
17. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10.
18. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23.
19. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73:970-7.
20. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9.
21. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther 2006;109:173-97.
22. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002;277:14294-8.
23. Zhang Z, Dickerson IM, Russo AF. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology 2006;147:1932-40.
24. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 2007;27:2693-703.
25. Marquez de Prado B, Hammond DL, Russo AF. Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. J Pain 2009;10:992-1000.
26. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123 ( Pt 8):1703-9.
27. LoPinto C, Young WB, Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 2006;26:852-6.
28. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-10.
29. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24.
30. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 2004;18:337-42.
31. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-70.
32. Mulleners WM, Aurora SK, Chronicle EP, Stewart R, Gopal S, Koehler PJ. Self-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accurately. Headache 2001;41:31-9.
33. Bohnen N, Twijnstra A, Wijnen G, Jolles J. Recovery from visual and acoustic hyperaesthesia after mild head injury in relation to patterns of behavioural dysfunction. J Neurol Neurosurg Psychiatry 1992;55:222-4.
34. Du T, Ciuffreda KJ, Kapoor N. Elevated dark adaptation thresholds in traumatic brain injury. Brain Inj 2005;19:1125-38.
35. Irimia P, Cittadini E, Paemeleire K, Cohen AS, Goadsby PJ. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia 2008;28:626-30.
36. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002;58:354-61.
37. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994;117 ( Pt 3):427-34.
38. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008;71:1275-82.
39. Theeler BJ, Erickson JC. Mild head trauma and chronic headaches in returning US soldiers. Headache 2009;49:529-34.
40. Neely ET, Midgette LA, Scher AI. Clinical review and epidemiology of headache disorders in US service members: with emphasis on post-traumatic headache. Headache 2009;49:1089-96.
41. Lew HL, Poole JH, Vanderploeg RD, et al. Program development and defining characteristics of returning military in a VA Polytrauma Network Site. J Rehabil Res Dev 2007;44:1027-34.
42. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980;13:167-70.
43. Blumstein LK, Crawley JN. Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1983;18:37-40.
44. Bourin M, Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003;463:55-65.
45. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 2009;29:8798-804.
46. Recober A, Kaiser EA, Kuburas A, Russo AF. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology 2009.
47. Thiels E, Hoffman EK, Gorin MB. A reliable behavioral assay for the assessment of sustained photophobia in mice. Curr Eye Res 2008;33:483-91.
48. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Determinants of BIBN4096BS affinity for CGRP and amylin receptors; the role of RAMP1. Mol Pharmacol 2006.\
49. Okamoto K, Thompson R, Tashiro A, Chang Z, Bereiter DA. Bright light produces Fos-positive neurons in caudal trigeminal brainstem. Neuroscience 2009;160:858-64.
50. Drummond PD, Woodhouse A. Painful stimulation of the forehead increases photophobia in migraine sufferers. Cephalalgia 1993;13:321-4.
51. Kowacs PA, Piovesan EJ, Werneck LC, et al. Influence of intense light stimulation on trigeminal and cervical pain perception thresholds. Cephalalgia 2001;21:184-8.
52. Moulton EA, Becerra L, Borsook D. An fMRI case report of photophobia: activation of the trigeminal nociceptive pathway. Pain 2009;145:358-63.
53. Amini A, Digre K, Couldwell WT. Photophobia in a blind patient: An alternate visual pathway. Case report. J Neurosurg 2006;105:765-8.
54. Herz NL, Yen MT. Modulation of sensory photophobia in essential blepharospasm with chromatic lenses. Ophthalmology 2005;112:2208-11.
55. Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ. The evaluation of light sensitivity in benign essential blepharospasm. Am J Ophthalmol 2006;142:82-7.
56. Blackburn MK, Lamb RD, Digre KB, et al. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. Ophthalmology 2009;116:997-1001.
57. Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 2008;1196:22-32.
58. Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain 2009;5:43.